ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding ProPhase Labs, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 27 | 30 | +3 |
| Shares | 1.75M | 2.42M | +667.0K (+38.1%) |
| Value | $4.23M | $1.91M | −$2.32M (−54.8%) |
New holders (8)
Institutions that held ProPhase Labs, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sheets Smith Wealth Management | 208,300 | $157.7K | 0.02% |
| Warberg Asset Management LLC | 101,672 | $77.0K | 0.02% |
| Squarepoint Ops LLC | 52,394 | $39.7K | 0.00% |
| Boston Private Wealth LLC | 47,665 | $36.1K | 0.00% |
| United Capital Management of KS, Inc. | 34,700 | $26.3K | 0.00% |
| Engineers Gate Manager LP | 15,974 | $12.1K | 0.00% |
| SBI Securities Co., Ltd. | 404 | $306 | 0.00% |
| Tower Research Capital LLC (TRC) | 116 | $88 | 0.00% |
Sold out (5)
Institutions that held ProPhase Labs, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Bridgeway Capital Management, LLC | 23,095 | $55.9K |
| Commonwealth Equity Services, LLC | 13,362 | $32.0K |
| Barclays PLC | 11,767 | $28.5K |
| Advisor Group Holdings, Inc. | 2,000 | $4.84K |
| Jamison Private Wealth Management, Inc. | 3,000 | $0 |